Top

Molecular Cancer

Published in:

Open Access 01-12-2012 | Research

The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma

Authors: Anna Djos, Tommy Martinsson, Per Kogner, Helena Carén

Published in: Molecular Cancer | Issue 1/2012

Abstract

Background

Hypermethylation of promotor CpG islands is a common mechanism that inactivates tumor suppressor genes in cancer. Genes belonging to the RASSF gene family have frequently been reported as epigenetically silenced by promotor methylation in human cancers. Two members of this gene family, RASSF1A and RASSF5A have been reported as methylated in neuroblastoma. Data from our previously performed genome-wide DNA methylation array analysis indicated that other members of the RASSF gene family are targeted by DNA methylation in neuroblastoma.

Results

In the current study, we found that several of the RASSF family genes (RASSF2, RASSF4, RASSF5, RASSF6, RASSF7, and RASSF10) to various degrees were methylated in neuroblastoma cell lines and primary tumors. In addition, several of the RASSF family genes showed low or absent mRNA expression in neuroblastoma cell lines. RASSF5 and RASSF6 were to various degrees methylated in a large portion of neuroblastoma tumors and RASSF7 was heavily methylated in most tumors. Further, CpG methylation sites in the CpG islands of some RASSF family members could be used to significantly discriminate between biological subgroups of neuroblastoma tumors. For example, RASSF5 methylation highly correlated to MYCN amplification and INRG stage M. Furthermore, high methylation of RASSF6 was correlated to unfavorable outcome, 1p deletion and MYCN amplification in our tumor material.

In conclusion

This study shows that several genes belonging to the RASSF gene family are methylated in neuroblastoma. The genes RASSF5, RASSF6 and RASSF7 stand out as the most promising candidate genes for further investigations in neuroblastoma.

Available only for authorised users

Johnsen JI, Kogner P, Albihn A, Henriksson MA: Embryonal neural tumours and cell death. Apoptosis. 2009, 14 (4): 424-438. 10.1007/s10495-009-0325-yCrossRefPubMed

Brodeur GM: Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003, 3 (3): 203-216. 10.1038/nrc1014CrossRefPubMed

Carén H, Kryh H, Nethander M, Sjöberg RM, Träger C, Nilsson S, Abrahamsson J, Kogner P, Martinsson T: High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci U S A. 2010, 107 (9): 4323-4328. 10.1073/pnas.0910684107PubMedCentralCrossRefPubMed

Astuti D, Agathanggelou A, Honorio S, Dallol A, Martinsson T, Kogner P, Cummins C, Neumann HP, Voutilainen R, Dahia P: RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours. Oncogene. 2001, 20 (51): 7573-7577. 10.1038/sj.onc.1204968CrossRefPubMed

Ejeskär K, Aburatani H, Abrahamsson J, Kogner P, Martinsson T: Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene. Br J Cancer. 1998, 77 (11): 1787-1791. 10.1038/bjc.1998.297CrossRefPubMed

Donninger H, Vos MD, Clark GJ: The RASSF1A tumor suppressor. J Cell Sci. 2007, 120 (Pt 18): 3163-3172.CrossRefPubMed

Cully M, Downward J: SnapShot: Ras Signaling. Cell. 2008, 133 (7): 1292-1292 e1291. 10.1016/j.cell.2008.06.020CrossRefPubMed

Sherwood V, Manbodh R, Sheppard C, Chalmers AD: RASSF7 is a member of a new family of RAS association domain-containing proteins and is required for completing mitosis. Mol Biol Cell. 2008, 19 (4): 1772-1782. 10.1091/mbc.E07-07-0652PubMedCentralCrossRefPubMed

Carén H, Djos A, Nethander M, Sjöberg RM, Kogner P, Enström C, Nilsson S, Martinsson T: Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma. BMC Cancer. 2011, 11 (1): 66- 10.1186/1471-2407-11-66PubMedCentralCrossRefPubMed

10.

Hesson LB, Dunwell TL, Cooper WN, Catchpoole D, Brini AT, Chiaramonte R, Griffiths M, Chalmers AD, Maher ER, Latif F: The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol Cancer. 2009, 8: 42- 10.1186/1476-4598-8-42PubMedCentralCrossRefPubMed

11.

Kryh H, Carén H, Erichsen J, Sjöberg RM, Abrahamsson J, Kogner P, Martinsson T: Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors. BMC Genomics. 2011, 12: 443- 10.1186/1471-2164-12-443PubMedCentralCrossRefPubMed

12.

Tusnady GE, Simon I, Varadi A, Aranyi T: BiSearch: primer-design and search tool for PCR on bisulfite-treated genomes. Nucleic Acids Res. 2005, 33 (1): e9- 10.1093/nar/gni012PubMedCentralCrossRefPubMed

13.

Hesson LB, Wilson R, Morton D, Adams C, Walker M, Maher ER, Latif F: CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. Oncogene. 2005, 24 (24): 3987-3994. 10.1038/sj.onc.1208566CrossRefPubMed

14.

Eckfeld K, Hesson L, Vos MD, Bieche I, Latif F, Clark GJ: RASSF4/AD037 is a potential ras effector/tumor suppressor of the RASSF family. Cancer Res. 2004, 64 (23): 8688-8693. 10.1158/0008-5472.CAN-04-2065CrossRefPubMed

15.

Akino K, Toyota M, Suzuki H, Mita H, Sasaki Y, Ohe-Toyota M, Issa JP, Hinoda Y, Imai K, Tokino T: The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology. 2005, 129 (1): 156-169. 10.1053/j.gastro.2005.03.051CrossRefPubMed

16.

Xiong Z, Laird PW: COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 1997, 25 (12): 2532-2534. 10.1093/nar/25.12.2532PubMedCentralCrossRefPubMed

17.

Carén H, Fransson S, Ejeskär K, Kogner P, Martinsson T: Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumours. Br J Cancer. 2007, 97 (10): 1416-1424. 10.1038/sj.bjc.6604032PubMedCentralCrossRefPubMed

18.

Tommasi S, Dammann R, Zhang Z, Wang Y, Liu L, Tsark WM, Wilczynski SP, Li J, You M, Pfeifer GP: Tumor susceptibility of Rassf1a knockout mice. Cancer Res. 2005, 65 (1): 92-98.PubMed

19.

van der Weyden L, Tachibana KK, Gonzalez MA, Adams DJ, Ng BL, Petty R, Venkitaraman AR, Arends MJ, Bradley A: The RASSF1A isoform of RASSF1 promotes microtubule stability and suppresses tumorigenesis. Mol Cell Biol. 2005, 25 (18): 8356-8367. 10.1128/MCB.25.18.8356-8367.2005PubMedCentralCrossRefPubMed

20.

Endoh M, Tamura G, Honda T, Homma N, Terashima M, Nishizuka S, Motoyama T: RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer. Br J Cancer. 2005, 93 (12): 1395-1399. 10.1038/sj.bjc.6602854PubMedCentralCrossRefPubMed

21.

Zhang Z, Sun D: Van do N, Tang A, Hu L, Huang G: Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Int J Cancer. 2007, 120 (1): 32-38. 10.1002/ijc.22185CrossRefPubMed

22.

Cooper WN, Dickinson RE, Dallol A, Grigorieva EV, Pavlova TV, Hesson LB, Bieche I, Broggini M, Maher ER, Zabarovsky ER: Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer. Oncogene. 2008, 27 (12): 1805-1811. 10.1038/sj.onc.1210805PubMedCentralCrossRefPubMed

23.

Schagdarsurengin U, Richter AM, Hornung J, Lange C, Steinmann K, Dammann RH: Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences. Mol Cancer. 2010, 9: 264- 10.1186/1476-4598-9-264PubMedCentralCrossRefPubMed

24.

Zhao L, Cui Q, Lu Z, Chen J: Aberrant Methylation of RASSF2A in Human Pancreatic Ductal Adenocarcinoma and Its Relation to Clinicopathologic Features. Pancreas. 2012, 41 (2): 206-211. 10.1097/MPA.0b013e318223d1a5CrossRefPubMed

25.

Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ, Clark GJ: RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem. 2003, 278 (30): 28045-28051. 10.1074/jbc.M300554200CrossRefPubMed

26.

Lazcoz P, Munoz J, Nistal M, Pestana A, Encio I, Castresana JS: Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma. BMC Cancer. 2006, 6: 254- 10.1186/1471-2407-6-254PubMedCentralCrossRefPubMed

27.

Geli J, Kogner P, Lanner F, Natalishvili N, Juhlin C, Kiss N, Clark GJ, Ekstrom TJ, Farnebo F, Larsson C: Assessment of NORE1A as a putative tumor suppressor in human neuroblastoma. Int J Cancer. 2008, 123 (2): 389-394. 10.1002/ijc.23533CrossRefPubMed

28.

Hesson L, Dallol A, Minna JD, Maher ER, Latif F: NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene. 2003, 22 (6): 947-954. 10.1038/sj.onc.1206191CrossRefPubMed

29.

Morris MR, Hesson LB, Wagner KJ, Morgan NV, Astuti D, Lees RD, Cooper WN, Lee J, Gentle D, Macdonald F: Multigene methylation analysis of Wilms’ tumour and adult renal cell carcinoma. Oncogene. 2003, 22 (43): 6794-6801. 10.1038/sj.onc.1206914CrossRefPubMed

30.

Chen J, Lui WO, Vos MD, Clark GJ, Takahashi M, Schoumans J, Khoo SK, Petillo D, Lavery T, Sugimura J: The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas. Cancer Cell. 2003, 4 (5): 405-413. 10.1016/S1535-6108(03)00269-1CrossRefPubMed

31.

Steinmann K, Sandner A, Schagdarsurengin U, Dammann RH: Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma. Oncol Rep. 2009, 22 (6): 1519-1526.PubMed

32.

Macheiner D, Gauglhofer C, Rodgarkia-Dara C, Grusch M, Brachner A, Bichler C, Kandioler D, Sutterluty H, Mikulits W, Schulte-Hermann R: NORE1B is a putative tumor suppressor in hepatocarcinogenesis and may act via RASSF1A. Cancer Res. 2009, 69 (1): 235-242. 10.1158/0008-5472.CAN-08-2144CrossRefPubMed

33.

Ortiz-Vega S, Khokhlatchev A, Nedwidek M, Zhang XF, Dammann R, Pfeifer GP, Avruch J: The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene. 2002, 21 (9): 1381-1390. 10.1038/sj.onc.1205192CrossRefPubMed

34.

Calvisi DF, Donninger H, Vos MD, Birrer MJ, Gordon L, Leaner V, Clark GJ: NORE1A tumor suppressor candidate modulates p21CIP1 via p53. Cancer Res. 2009, 69 (11): 4629-4637. 10.1158/0008-5472.CAN-08-3672CrossRefPubMed

35.

Ikeda M, Hirabayashi S, Fujiwara N, Mori H, Kawata A, Iida J, Bao Y, Sato Y, Iida T, Sugimura H: Ras-association domain family protein 6 induces apoptosis via both caspase-dependent and caspase-independent pathways. Exp Cell Res. 2007, 313 (7): 1484-1495. 10.1016/j.yexcr.2007.02.013CrossRefPubMed

36.

Wen Y, Wang Q, Zhou C, Yan D, Qiu G, Yang C, Tang H, Peng Z: Decreased Expression of RASSF6 Is a Novel Independent Prognostic Marker of a Worse Outcome in Gastric Cancer Patients after Curative Surgery. Ann Surg Oncol. 2011 Dec, 18 (13): 3858-67. 10.1245/s10434-011-1668-5. 10.1245/s10434-011-1668-5CrossRefPubMed

37.

Recino A, Sherwood V, Flaxman A, Cooper WN, Latif F, Ward A, Chalmers AD: Human RASSF7 regulates the microtubule cytoskeleton and is required for spindle formation, Aurora B activation and chromosomal congression during mitosis. Biochem J. 2010, 430 (2): 207-213. 10.1042/BJ20100883PubMedCentralCrossRefPubMed

38.

Falvella FS, Manenti G, Spinola M, Pignatiello C, Conti B, Pastorino U, Dragani TA: Identification of RASSF8 as a candidate lung tumor suppressor gene. Oncogene. 2006, 25 (28): 3934-3938. 10.1038/sj.onc.1209422CrossRefPubMed

39.

Lock FE, Underhill-Day N, Dunwell T, Matallanas D, Cooper W, Hesson L, Recino A, Ward A, Pavlova T, Zabarovsky E: The RASSF8 candidate tumor suppressor inhibits cell growth and regulates the Wnt and NF-kappaB signaling pathways. Oncogene. 2010, 29 (30): 4307-4316. 10.1038/onc.2010.192CrossRefPubMed

40.

Schagdarsurengin U, Richter AM, Wohler C, Dammann RH: Frequent epigenetic inactivation of RASSF10 in thyroid cancer. Epigenetics. 2009, 4 (8): 571-576. 10.4161/epi.4.8.10056CrossRefPubMed

41.

Hill VK, Underhill-Day N, Krex D, Robel K, Sangan CB, Summersgill HR, Morris M, Gentle D, Chalmers AD, Maher ER: Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis. Oncogene. 2011, 30 (8): 978-989. 10.1038/onc.2010.471CrossRefPubMed

42.

Helmbold P, Richter AM, Walesch S, Skorokhod A, Marsch WC, Enk A, Dammann RH: RASSF10 Promoter Hypermethylation Is Frequent in Malignant Melanoma of the Skin but Uncommon in Nevus Cell Nevi. J Invest Dermatol. 2012 Mar, 132 (3 Pt 1): 687-94.CrossRefPubMed

43.

Das S, Foley N, Bryan K, Watters KM, Bray I, Murphy DM, Buckley PG, Stallings RL: MicroRNA mediates DNA demethylation events triggered by retinoic acid during neuroblastoma cell differentiation. Cancer Res. 2010, 70 (20): 7874-7881. 10.1158/0008-5472.CAN-10-1534PubMedCentralCrossRefPubMed

44.

Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, Kidd VJ: Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med. 2000, 6 (5): 529-535. 10.1038/75007CrossRefPubMed

45.

Decock A, Ongenaert M, Vandesompele J, Speleman F: Neuroblastoma epigenetics: from candidate gene approaches to genome-wide screenings. Epigenetics. 2011, 6 (8): 962-970. 10.4161/epi.6.8.16516CrossRefPubMed

46.

Yang Q, Zage P, Kagan D, Tian Y, Seshadri R, Salwen HR, Liu S, Chlenski A, Cohn SL: Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma. Clin Cancer Res. 2004, 10 (24): 8493-8500. 10.1158/1078-0432.CCR-04-1331CrossRefPubMed

47.

Misawa A, Tanaka S, Yagyu S, Tsuchiya K, Iehara T, Sugimoto T, Hosoi H: RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker. Br J Cancer. 2009, 100 (2): 399-404. 10.1038/sj.bjc.6604887PubMedCentralCrossRefPubMed

Title: The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma
Authors: Anna Djos
Tommy Martinsson
Per Kogner
Helena Carén
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2012
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-11-40

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Results

In conclusion

Please log in to get access to this content

Other articles of this Issue 1/2012

miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death

Osteoblast-secreted collagen upregulates paracrine Sonic hedgehog signaling by prostate cancer cells and enhances osteoblast differentiation

A possible primary cause of cancer: deficient cellular interactions in endocrine pancreas

Protective effect of the poly(ADP-ribose) polymerase inhibitor PJ34 on mitochondrial depolarization-mediated cell death in hepatocellular carcinoma cells involves attenuation of c-Jun N-terminal kinase-2 and protein kinase B/Akt activation

Silencing of Apoptosis-Inducing factor and poly (ADP-ribose) glycohydrolase reveals novel roles in breast cancer cell death after chemotherapy

Triplex DNA-binding proteins are associated with clinical outcomes revealed by proteomic measurements in patients with colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer